Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
This study will evaluate the safety of LBH589 given in combination with lenalidomide and dexamethasone in adult patients with multiple myeloma
Multiple Myeloma
DRUG: LBH589|COMBINATION_PRODUCT: Lenalidomide
To determine the highest and safest dose of LBH589 when it is administered in combination with lenalidomide & dexamethasone, 24 weeks
Safety and tolerability assessed by monitoring of adverse events, serious adverse events and laboratory parameters To characterize the pharmacokinetic profile of the study treatment To characterize the pharmacodynamic profile of the study treatment, Da1 to Day 3 (week 1 of first cycle)
This study will evaluate the safety of LBH589 given in combination with lenalidomide and dexamethasone in adult patients with multiple myeloma